taobanker
App Builder
Moderna has almost 40% downside to its average analyst price target of $119.56, which makes the sudden rush to buy it hard to explain. x.comÂ
Moderna generates one-tenth of Bristol Myers Squibb's revenue, making their nearly equal valuations hard to justify. x.comÂ
Moderna could get explosive above $200 as anyone who shorted last week's valuation downgrade has to cover. The shakeout on that downgrade was a killer opportunity, and the stock is now back over $200. x.comÂ
Moderna's approaching October 24 data release at a Madrid conference makes some pre-event profit-taking likely. After the release, the stock could be $400, $200 or $40; the outcome is unknown. x.comÂ
Moderna faces about 67% downside to the Wall Street analyst price target of $50.84 per share. x.com x.comÂ
Moderna looks like a logical play on plague-outbreak concerns, though this is outside areas of expertise. A Russian lab worker's sudden death has raised fears of a plague crisis, per Zero Hedge, with the Trump team monitoring the outbreak, and the stock is acting well. x.comÂ
Moderna remains unattractive despite forced Nasdaq-100 index buying: quarterly revenue is $145M against a $782M loss, while shares trade around $200. Citi rates it Sell with an $80 target. x.comÂ
Moderna looks overvalued at about $80B after its melanoma success sparked a retail frenzy. Its upcoming Phase 2 lung cancer and Phase 3 kidney cancer readouts target cold tumors, with much lower odds than melanoma, though success in either would fuel the rally further. January calls cost about 67% of the share price annualized, the most expensive option seen on an already overvalued stock. The retail-driven trend could continue in the short term. x.comÂ
Moderna could rise further with strong call flow showing, but it is getting close to a top expected in late October or early November; take profits on the way up. x.comÂ
Moderna is likely to drop a massive stock offering on the buyers piling in. It has only about $5 billion and is losing money every quarter, so raising as much as possible, perhaps $15-20 billion, would make sense while demand is plentiful. @A_May_MD doubts it could raise more than about $6 billion. x.com x.com x.com x.comÂ